The oral delivery of bioactive peptides and proteins is prevented by the intestinal epithelial barrier, in which intercellular tight junction complexes block the uptake of macromolecules. Here we show that anionic nanoparticles induce tight junction relaxation, increasing intestinal permeability and enabling the oral delivery of proteins. This permeation-enhancing effect is a function of nanoparticle size and charge, with smaller (≤ 200 nm) and more negative particles (such as silica) conferring enhanced permeability. In healthy mice, silica nanoparticles enabled the oral delivery of insulin and exenatide, with 10 U kg−1 orally delivered insulin sustaining hypoglycaemia for a few hours longer than a 1 U kg−1 dose of subcutaneously injected insulin. In healthy, hyperglycaemic and diabetic mice, the oral delivery of 10 U kg−1 insulin led to a dose-adjusted bioactivity of, respectively, 35%, 29% and 23% that of the subcutaneous injection of 1 U kg−1 insulin. The permeation-enhancing effect of the nanoparticles was reversible, non-toxic, and attributable to the binding to integrins on the surface of epithelial cells.
Subscribe to Journal
Get full journal access for 1 year
only $8.67 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The main data supporting the results in this study are available within the Article and Supplementary Information. The raw and analysed datasets generated during the study are available for research purposes from the corresponding authors on reasonable request.
McLenon, J. & Rogers, M. A. M. The fear of needles: a systematic review and meta-analysis. J. Adv. Nurs. 75, 30–42 (2018).
Howe, C. J., Ratcliffe, S. J., Tuttle, A., Dougherty, S. & Lipman, T. H. Needle anxiety in children with type 1 diabetes and their mothers. MCN Am. J. Matern. Child Nurs. 36, 25–31 (2011).
Sokolowski, C. J., Giovannitti, J. A. & Boynes, S. G. Needle phobia: etiology, adverse consequences, and patient management. Dent. Clin. North Am. 54, 731–734 (2010).
Peyrot, M., Rubin, R. R., Kruger, D. F. & Travis, L. B. Correlates of insulin injection omission. Diabetes Care 33, 240–245 (2010).
Zambanini, A., Newson, R. B., Maisey, M. & Feher, M. D. Injection related anxiety in insulin-treated diabetes. Diabetes Res. Clin. Pract. 46, 239–246 (1999).
Moroz, E., Matoori, S. & Leroux, J. C. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101, 108–121 (2015).
Morishita, M. & Peppas, N. A. Is the oral route possible for peptide and protein drug delivery?. Drug Discov. Today 11, 905–910 (2006).
Shen, L., Weber, C. R., Raleigh, D. R., Yu, D. & Turner, J. R. Tight junction pore and leak pathways: a dynamic duo. Annu. Rev. Physiol. 73, 283–309 (2011).
Mrsny, R. J. Oral drug delivery research in Europe. J. Control. Release 161, 247–253 (2012).
Walsh, E. G. et al. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET®). Ther. Deliv. 2, 1595–1610 (2011).
Banerjee, A. et al. Ionic liquids for oral insulin delivery. Proc. Natl Acad. Sci. USA 115, 7296–7301 (2018).
Fein, K. C., Lamson, N. G. & Whitehead, K. A. Structure-function analysis of phenylpiperazine derivatives as intestinal permeation enhancers. Pharm. Res. 34, 1320–1329 (2017).
Bzik, V. A. & Brayden, D. J. An assessment of the permeation enhancer, 1-phenyl-piperazine (PPZ), on paracellular flux across rat intestinal mucosae in Ussing chambers. Pharm. Res. 33, 2506–2516 (2016).
Zijlstra, E., Heinemann, L. & Plum-Mörschel, L. Oral insulin reloaded: a structured approach. J. Diabetes Sci. Technol. 8, 458–465 (2014).
Arbit, E. & Kidron, M. Oral insulin delivery in a physiologic context: review. J. Diabetes Sci. Technol. 11, 825–832 (2017).
Aguirre, T. A. S. et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106, 223–241 (2016).
Lamson, N. G., Cusimano, G., Suri, K., Zhang, A. & Whitehead, K. A. The pH of piperazine derivative solutions predicts their utility as transepithelial permeation enhancers. Mol. Pharm. 13, 578–585 (2016).
Whitehead, K., Karr, N. & Mitragotri, S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. 25, 1782–1788 (2008).
McCartney, F., Gleeson, J. P. & Brayden, D. J. Safety concerns over the use of intestinal permeation enhancers: a mini-review. Tissue Barriers 4, (2016).
Kam, K. R. et al. Nanostructure-mediated transport of biologics across epithelial tissue: enhancing permeability via nanotopography. Nano Lett. 13, 164–171 (2013).
Schoellhammer, C. M. et al. Ultrasound-mediated gastrointestinal drug delivery. Sci. Transl. Med. 7, 310ra168 (2015).
Fan, W. et al. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials 151, 13–23 (2018).
Zhu, X. et al. Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery. Mol. Pharm. 11, 317–328 (2014).
Liu, L. et al. pH- and amylase-responsive carboxymethyl starch/poly (2-isobutyl-acrylic acid) hybrid microgels as effective enteric carriers for oral insulin delivery. Biomacromolecules 19, 2123–2136 (2018).
Sheng, J. et al. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J. Control. Release 233, 181–190 (2016).
Shan, W. et al. Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers. ACS Appl. Mater. Interf. 8, 25444–25453 (2016).
Lee, J. H., Sahu, A., Choi, W. I., Lee, J. Y. & Tae, G. ZOT-derived peptide and chitosan functionalized nanocarrier for oral delivery of protein drug. Biomaterials 103, 160–169 (2016).
Wong, C. Y., Al-Salami, H. & Dass, C. R. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J. Control. Release 264, 247–275 (2017).
Larregieu, C. A. & Benet, L. Z. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. AAPS J. 15, 483–497 (2013).
Atuma, C., Strugala, V., Allen, A. & Holm, L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G922–G929 (2001).
Grießinger, J. et al. Methods to determine the interactions of micro- and nanoparticles with mucus. Eur. J. Pharm. Biopharm. 96, 464–476 (2015).
Bischoff, S. C. et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol. 14, 189 (2014).
Taverner, A. et al. Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J. Control. Release 210, 189–197 (2015).
Gupta, V. et al. Delivery of exenatide and insulin using mucoadhesive intestinal devices. Ann. Biomed. Eng. 44, 1993–2007 (2016).
Edgerton, D. S. et al. Insulin’s direct effects on the liver dominate the control of hepatic glucose production. J. Clin. Invest. 116, 521–527 (2006).
Morishita, I., Morishita, M., Takayama, K., Machida, Y. & Nagai, T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78, 9–16 (1992).
McConnell, E. L., Basit, A. W. & Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J. Pharm. Pharmacol. 60, 63–70 (2008).
Lowman, A. M., Morishita, M., Kajita, M., Nagai, T. & Peppas, N. A. Oral delivery of insulin using pH responsive complexation gels. J. Pharm. Sci. 88, 933–937 (1999).
Genovese, S., Mannucci, E. & Ceriello, A. A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes. Adv. Ther. 34, 1791–1814 (2017).
Wu, K. K. & Huan, Y. Streptozotocin-induced diabetic models in mice and rats. Curr. Protoc. Pharmacol. 70, 5.47.1–5.47.20 (2015).
Sun, H., Chow, E. C., Liu, S., Du, Y. & Pang, K. S. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 4, 395–411 (2008).
Lopes, M. A. et al. Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomed. Nanotechnol. Biol. Med. 10, 1139–1151 (2014).
Walsh, L. et al. Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism. Nano Lett. 15, 2434–2441 (2015).
Gilcrease, M. Z. Integrin signaling in epithelial cells. Cancer Lett. 247, 1–25 (2007).
Muller, W. A. Mechanisms of leukocyte transendothelial migration. Annu. Rev. Pathol. 6, 323–344 (2011).
Beaulieu, J.-F. Integrins and human intestinal cell functions. Front. Biosci. 4, 310–321 (1999).
Ölander, M., Wiśniewski, J. R., Matsson, P., Lundquist, P. & Artursson, P. The proteome of filter-grown Caco-2 cells with a focus on proteins involved in drug disposition. J. Pharm. Sci. 105, 817–827 (2016).
Salama, N. N., Eddington, N. D. & Fasano, A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58, 15–28 (2006).
Walczak, A. P. et al. Translocation of differently sized and charged polystyrene nanoparticles in in vitro intestinal cell models of increasing complexity. Nanotoxicology 9, 453-461 (2014).
Yu, S. H. et al. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. Acta Biomater. 9, 7449–7459 (2013).
Murugadoss, S. et al. Toxicology of silica nanoparticles: an update. Arch. Toxicol. 91, 2967–3010 (2017).
Whitehead, K., Shen, Z. & Mitragotri, S. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J. Control. Release 98, 37–45 (2004).
Banerjee, A., Lee, J. & Mitragotri, S. Intestinal mucoadhesive devices for oral delivery of insulin. Bioeng. Transl. Med. 1, 338–346 (2016).
Young, L., Sung, J., Stacey, G. & Masters, J. R. Detection of Mycoplasma in cell cultures. Nat. Protoc. 5, 929–934 (2010).
Chong, S., Dando, S. A. & Morrison, R. A. Evaluation of Biocoat® Intestinal Epithelium Differentiation Environment (3-day cultured Caco-2 cells) as an absorption screening model with improved screening productivity. Pharm. Res. 14, 1835–1837 (1997).
Yamashita, S. et al. New and better protocols for a short-term Caco-2 cell culture system. J. Pharm. Sci. 91, 669–679 (2002).
Gupta, V., Doshi, N. & Mitragotri, S. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLoS ONE 8, e57136 (2013).
Xu, Q. et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 9, 9217–9227 (2015).
Pereira De Sousa, I. et al. Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles. Eur. J. Pharm. Biopharm. 97, 273–279 (2015).
Ball, R. L., Knapp, C. M. & Whitehead, K. A. Lipidoid nanoparticles for siRNA delivery to the intestinal epithelium: in vitro investigations in a Caco-2 model. PLoS ONE 10, e0133154 (2015).
The authors thank L. Kasiewicz for her assistance in revising and editing this manuscript. They also acknowledge M. Koval (Emory University) for his guidance on examining tight junctions. N.G.L. acknowledges funding support from the Thomas and Adrienne Klopack Graduate Fellowship and National Science Foundation Graduate Research Fellowship Program (NSF GRFP). This material is based on work supported by the NSF GRFP under grant no. DGE1252522. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NSF. The authors also acknowledge support from the National Institutes of Health, grant no. 1DP2OD026005-01.
K.A.W. and N.G.L. are registered as inventors on Patent Cooperation Treaty (PCT) application PCT/US2018/042035, which covers aspects of the technology presented here.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lamson, N.G., Berger, A., Fein, K.C. et al. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat Biomed Eng 4, 84–96 (2020). https://doi.org/10.1038/s41551-019-0465-5
Advanced Drug Delivery Reviews (2020)
Topical application of nanoparticles integrated supramolecular hydrogels for the potential treatment of seborrhoeic dermatitis
Pharmaceutical Development and Technology (2020)
Nutraceutical nanodelivery; an insight into the bioaccessibility/bioavailability of different bioactive compounds loaded within nanocarriers
Critical Reviews in Food Science and Nutrition (2020)
Journal of Controlled Release (2020)
Combinatorial Library of Cyclic Benzylidene Acetal-Containing pH-Responsive Lipidoid Nanoparticles for Intracellular mRNA Delivery
Bioconjugate Chemistry (2020)